OXT and prostate carcinoma: Additionally, compound 14 was able (i) to block the activation of Gαi2 in oxytocin-stimulated prostate cancer PC3 cells; (ii) to induce the phosphorylation of CREB protein, downstream effector of cAMP production; (iii) to negatively regulate the migration of the renal and ovarian cancer cell lines.